Sarcoidosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Sarcoidosis - Pipeline Review, H2 2015’, provides an overview of the Sarcoidosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sarcoidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcoidosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sarcoidosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Sarcoidosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Sarcoidosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration
till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Sarcoidosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Sarcoidosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Sarcoidosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

**Table Of Contents:**

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Sarcoidosis Overview 6
Therapeutics Development 7
Pipeline Products for Sarcoidosis - Overview 7
Pipeline Products for Sarcoidosis - Comparative Analysis 8
Sarcoidosis - Therapeutics under Development by Companies 9
Sarcoidosis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Sarcoidosis - Products under Development by Companies 12
Sarcoidosis - Companies Involved in Therapeutics Development 13
Arim Pharmaceuticals Inc. 13
Celgene Corporation 14
FirstString Research, Inc. 15
Novartis AG 16
PharmaIN Corporation 17
Sarcoidosis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ABS-11 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
apremilast - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
canakinumab - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CC-220 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
cibinetide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
eprodisate disodium - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
PGC-VIP - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Companies Mentioned:

Araim Pharmaceuticals Inc.
Celgene Corporation
FirstString Research, Inc.
Novartis AG
PharmaIN Corporation

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.
Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Global License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL: https://www.marketresearchreports.com/global-markets-direct/sarcoidosis-pipeline-review-h2-2015

Links